Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
Allergy · 2026-02 · 81 (2) · 326-344
DOI: 10.1111/all.70061 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 24.09.2025. Verfasst von Marjolein S de Bruin-Weller und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlan…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Biological Products. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro‐inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL‐4 and IL‐13 signaling, while tralokinumab and lebrikizumab selectively block IL‐13. Nemolizumab targets IL‐31, which plays a crucial role in pruritus. This review summarizes primarily real‐world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Clinical Medicine, Trinity College, Dublin, Ireland.
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
ORCID-Profile: Marjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten, Alan D Irvine, Daphne S Bakker, Stephan Weidinger
Zitieren
APA
de Bruin-Weller, M. S., Boesjes, C. M., Achten, R. A., Beck, L. A., Irvine, A. D., Vestergaard, C., de Graaf, M., van Wijk, F., Bakker, D. S., & Weidinger, S. (2026). Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. Allergy, 81(2), 326-344. https://doi.org/10.1111/all.70061
Vancouver
de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, et al. Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. Allergy. 2026;81(2):326-344. doi:10.1111/all.70061
BibTeX
@article{deBruinWeller2026,
author = {de Bruin-Weller, Marjolein S and Boesjes, Celeste M and Achten, Roselie A and Beck, Lisa A and Irvine, Alan D and Vestergaard, Christian and de Graaf, Marlies and van Wijk, Femke and Bakker, Daphne S and Weidinger, Stephan},
title = {Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions},
journal = {Allergy},
year = {2026},
volume = {81},
number = {2},
pages = {326--344},
doi = {10.1111/all.70061}
}
EUVIMED